Insulet Corporation (PODD)

Currency in USD
330.77
+2.92(+0.89%)
Closed·
333.50+2.73(+0.83%)
·
PODD Scorecard
Full Analysis
14 analysts have revised their earnings upwards for the upcoming period
PODD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
328.08333.22
52 wk Range
180.31334.18
Key Statistics
Prev. Close
327.85
Open
329.85
Day's Range
328.08-333.22
52 wk Range
180.31-334.18
Volume
499.58K
Average Volume (3m)
719.65K
1-Year Change
78.76%
Book Value / Share
20.79
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PODD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
353.39
Upside
+6.84%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Insulet Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Insulet Corporation Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation SWOT Analysis


Diabetes Tech Leade
Insulet's Omnipod system drives 30% worldwide growth, with Q1 2025 sales exceeding expectations and prompting upward revision of revenue guidance
Market Expansion
Explore Insulet's strategic focus on the Type 2 diabetes market, representing over 30% of new customers and offering significant growth potential
Global Reach
Delve into Insulet's international success, with recent launches in Canada and Switzerland contributing to robust growth beyond U.S. borders
Analyst Optimism
Learn about analyst price targets ranging from $266 to $360, reflecting confidence in Insulet's market position and growth prospects
Read full SWOT analysis

Insulet Corporation Earnings Call Summary for Q2/2025

  • Insulet's Q2 2025 EPS of $1.17 beat forecasts by 27.17%, with revenue reaching $649M, up 31% YoY
  • Stock surged 14.68% in pre-market trading to $318 following strong earnings and raised guidance
  • Full-year revenue growth guidance increased to 24-27%, marking 10th consecutive year of 20%+ growth
  • Omnipod 5 driving innovation and market expansion, with focus on type 2 diabetes segment
  • Company maintains strong financial health with $1.1B cash reserves and 17.8% adjusted operating margin
Last Updated: 07/08/2025, 17:08
Read Full Transcript

Compare PODD to Peers and Sector

Metrics to compare
PODD
Peers
Sector
Relationship
P/E Ratio
98.6x−4.6x−0.6x
PEG Ratio
−2.53−0.190.00
Price/Book
15.9x3.5x2.6x
Price / LTM Sales
9.9x3.7x3.3x
Upside (Analyst Target)
6.7%47.4%38.0%
Fair Value Upside
Unlock5.5%4.4%Unlock

Analyst Ratings

21 Buy
3 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 353.39
(+6.84% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
1.17 / 0.92
Revenue / Forecast
649.10M / 614.18M
EPS Revisions
Last 90 days

PODD Income Statement

People Also Watch

766.24
AXON
+0.36%
607.07
GEV
+0.18%
207.59
LULU
+4.75%
711.68
LLY
+0.26%
106.17
BSX
+0.91%

FAQ

What Stock Exchange Does Insulet Trade On?

Insulet is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Insulet?

The stock symbol for Insulet is "PODD."

What Is the Insulet Market Cap?

As of today, Insulet market cap is 23.30B.

What Is Insulet's Earnings Per Share (TTM)?

The Insulet EPS (TTM) is 3.36.

When Is the Next Insulet Earnings Date?

Insulet will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is PODD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Insulet Stock Split?

Insulet has split 0 times.

How Many Employees Does Insulet Have?

Insulet has 3900 employees.

What is the current trading status of Insulet (PODD)?

As of 24 Aug 2025, Insulet (PODD) is trading at a price of 330.77, with a previous close of 327.85. The stock has fluctuated within a day range of 328.08 to 333.22, while its 52-week range spans from 180.31 to 334.18.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.